Welcome to our dedicated page for Odyssey Health SEC filings (Ticker: ODYY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a medical-device company’s regulatory maze isn’t easy—especially when Odyssey Health’s filings detail concussion therapeutics, R&D pivots, and licensing deals in dense scientific language. If you’ve ever searched for “Odyssey Health SEC filings explained simply” or wondered why a single footnote changes revenue projections, you know the challenge.
Stock Titan solves it. Our platform applies AI to every Odyssey Health quarterly earnings report 10-Q filing, Odyssey Health annual report 10-K simplified, and Odyssey Health 8-K material events explained, translating technical disclosures into clear takeaways. Want insider confidence signals? Track Odyssey Health insider trading Form 4 transactions and get Odyssey Health Form 4 insider transactions real-time alerts before the market closes. Need quick context on clinical-trial budgets? Our AI highlights the exact tables—no scrolling through 200 pages.
Investors use these insights to monitor R&D burn, compare milestone payments, and spot executive sentiment via Odyssey Health executive stock transactions Form 4. The page also links to the proxy for governance questions—including Odyssey Health proxy statement executive compensation—and offers an “earnings lens” that delivers instant Odyssey Health earnings report filing analysis. Whether you’re understanding Odyssey Health SEC documents with AI for a deep-dive valuation or just need a quick citation for a research note, you’ll find every form—from S-1s to 20-F equivalents—updated the moment EDGAR releases them, complete with easy keyword search, segment charts, and exportable data.
Odyssey Health, Inc. (ODYY) Schedule 13G/A shows a significant shareholder position by individual investor Jonathan D. Lutz. He reports beneficial ownership of 7,239,595 shares of Odyssey Health common stock, representing 7.3% of the outstanding class. Lutz, a U.S. citizen, has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. He certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, indicating a passive investment status under the applicable SEC rules.
Odyssey Health, Inc. entered a long-term Maintenance Agreement with Mast Hill Fund under which Odyssey will provide facility services through the first business day of February 2034. Mast Hill or its designee will pay service fees totaling approximately $245,000 per year.
In exchange for these fees, Odyssey issued Mast Hill a $2,262,000 convertible promissory note bearing 10% annual interest and maturing on November 13, 2026, convertible into common stock at 85% of the lowest volume weighted average price over the preceding 10 trading days. Odyssey will remit net service fees to Mast Hill as payments on this note.
Odyssey also signed a Securities Purchase Agreement allowing issuance of a convertible note of up to $25,000,000 in multiple tranches with a 10% original issue discount, implying maximum proceeds of $22,250,000 before costs, convertible on the same 85% VWAP formula. The first $500,000 tranche delivered net proceeds of $437,500 and included Warrants for 1,538,461 shares at $0.001 per share, with a requirement to have an effective registration statement within 60 days of each tranche.
Odyssey Health (OTC: ODYY) filed its annual report for the year ended July 31, 2025. The company remains a development-stage medical products business with no FDA-cleared or approved products and no commercial revenue. Management discloses substantial doubt about its ability to continue as a going concern.
As of July 31, 2025, current liabilities were $7,004,421 against current assets of $49,723, resulting in a working capital deficit of $6,954,698. Net loss allocable to common stockholders was $1,742,691 for the period, and the accumulated deficit reached $62,745,837. The aggregate market value of non‑affiliate equity was $1,770,764 as of January 31, 2025, based on a $0.0215 last sale price. Shares outstanding were 99,853,763 as of October 29, 2025.
The portfolio includes CardioMap (heart monitoring) and the Save‑A‑Life choking rescue device; neither has FDA clearance or approval. Due to funding constraints, Save‑A‑Life is prioritized, while CardioMap development is suspended in the near term. The company reports two employees and plans to rely on third‑party partners for manufacturing and distribution if products are cleared.
Odyssey Health, Inc. entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc., securing exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The agreement includes customary representations, warranties, covenants, and mutual indemnification, and contemplates customary ancillary documents at closing. The company highlighted risks tied to development and commercialization timelines, funding needs, and intellectual property protection. On October 16, 2025, Odyssey issued a press release announcing the signing; it is filed as Exhibit 99.1, with the agreement as Exhibit 10.1.
FAQ
What is the current stock price of Odyssey Health (ODYY)?
What is the market cap of Odyssey Health (ODYY)?
